PharmaJet has announced compelling results from a groundbreaking implementation study in Nigeria, showing that their Tropis® ID Needle-free System significantly enhances polio immunization coverage, reduces costs, and gains widespread support among healthcare workers. The study, conducted with partners including Nigeria’s National Primary Health Care Development Agency, Jhpiego, PATH, and the Sydani Group, demonstrated that Tropis increased coverage for the second dose of inactivated polio vaccine (IPV2) by 11.2% compared to traditional needle-based methods, offering a crucial boost in areas where maintaining polio immunity is essential. The switch to Tropis could save Nigeria’s immunization program nearly $50 million over five years, with total immunization costs dropping by up to 47%.
Designed to streamline vaccine administration, the Tropis system delivers fractional IPV (fIPV) doses intradermally without needles, making it a safer, faster, and more comfortable option than standard intramuscular injections. The study revealed a strong preference for Tropis among healthcare workers, with 95% favoring it as a new standard for routine polio vaccinations due to ease of use and reduced discomfort for patients. Nearly all caregivers involved indicated they would be more likely to return for future immunizations if Tropis was used, highlighting the potential for sustained community engagement in immunization programs.
Conducted over six months with USAID funding, this project represents a significant step forward in expanding Nigeria’s capacity to maintain polio eradication efforts. The Tropis study has garnered attention from health experts, with results presented at an event attended by representatives from Nigeria’s Federal Ministry of Health, the WHO, UNICEF, and USAID. The data, to be shared at the American Society of Tropical Medicine and Hygiene (ASTMH) annual meeting in November 2024, is expected to contribute valuable insights to global immunization strategies.
“This is a breakthrough for polio immunization efforts, particularly in high-risk regions,” said Paul LaBarre, PharmaJet’s Vice President of Global Business Development. “On this World Polio Day, we’re proud to stand alongside our partners and renew our commitment to the Global Polio Eradication Initiative.”
For more on PharmaJet’s Tropis system and its impact on global immunization, visit PharmaJet.
About PharmaJet
The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, and promote a preferred patient and caregiver experience while being safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet to improve the impact of your novel development program, visit https://pharmajet.com or contact PharmaJet here. Follow us on LinkedIn.
About Tropis ID
The PharmaJet Tropis® ID Precision Delivery System™ was developed with support from the World Health Organization, US CDC, and the Bill & Melinda Gates Foundation and has CE Mark and is WHO Prequalified for intradermal injections. It has been used for millions of injections in multiple immunization campaigns worldwide. Data have repeatedly shown improved immunogenicity for nucleic acid vaccines and therapeutics administered with Tropis compared to needle and syringe and electroporation delivery. In addition, Tropis is the exclusive intradermal delivery system for two authorized novel Covid-19 vaccines: ZyCoV-D by Zydus Lifesciences, and GEMCOVAC-OM by Gennova Biopharmaceuticals.
